Conclusion

With due attention to our literature and the recent findings in the wake of the COVID-19 outbreak, it can be postulated that Thymosin α1 might be of great clinical value in management of patients with progressed disease, especially the elderly who are more vulnerable to complications such as lymphocytopenia and ARDS as a result of SARS-CoV-2 infection. The positive regulatory effect of this thymic hormone in development and proliferation of T cells is a well-known fact that cannot be overlooked, especially amid the COVID-19 pandemic. Further research and clinical trials are required to shed more light on the effectiveness of Thymosin α1 at improving patient survival in a world afflicted with COVID-19.
Keywords : Thymosin α1, Lymphocytopenia, T cells, COVID-19, SARS-CoV-2